ViroPharma Looks To Cinryze To Drive Sales As Vancocin Faces Likely Generic Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech's HAE drug exceeded sales expectations during the second quarter, but FDA cites the company for misleading promotion.
You may also be interested in...
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.
Berinert Claims Another Part Of The HAE Orphan Market, But May Leave Room
FDA's approval of CSL Behring's Berinert for treatment of acute attacks of hereditary angioedema specifically mentions only two types of attacks. By approving the C1 esterase inhibitor with a targeted indication, the agency could be leaving open a window in the orphan exclusivity for another approval